Hanyu Pharmaceutical HY3000 Nasal Spray Phase I Phase I Clinical Test Welcome Progress

E Company News on September 9th, Shenzhen Hanyu Pharmaceutical Co., Ltd. and the Institute of Microbiology of the Chinese Academy of Sciences Co., Ltd., Anti -New Corolutic Polypeptide Drugs HY3000 Nasal Jets Limit Light Clinical Test at Shenzhen Third People's Hospital completed the first subject admission group This means that the clinical trial of the project has entered a substantive period of development. HY3000 nasal injection agents are used to prevent the prevention of new crown pneumonia through nasal injection.

According to the company's information, Shenzhen Hanyu Pharmaceutical Co., Ltd. was established in April 2003. It is a "national high -tech enterprise" specializing in the development, production and sales of polypeptide drugs. The company was listed on the Shenzhen Stock Exchange in 2011 (Securities abbreviated as: Hanyu Pharmaceutical, Securities Code: 300199), with a registered capital of 917 million yuan. Hanyu Pharmaceutical has a branch of Pingshan Branch, Wuhan subsidiary, Hong Kong subsidiaries, Gansu Chengji subsidiaries, Yunnan subsidiaries, German subsidiaries and other branches. Customer custom peptides, beauty peptides, polypeptide drugs, solid preparation drugs, medical devices and polypeptide skin care products.

The company has 24 polypeptide drugs, 9 new drug certificates, and 24 clinical approvals. The company's multiple materials and preparations have passed GMP certification inspections such as the United States, the European Union, South Korea, Brazil, etc., and have been sold to overseas markets. Pingshan Branch's polypeptide injection production base has passed the EU CGMP certification and established a marketing network in many countries. As a national high -tech enterprise, the company has established Guangdong Polypenic Pharmaceutical Engineering Technology Research and Development Center, Polymptide Drugs National Local Joint Engineering Laboratory, National Polyptide Innovation Public Experiment Center, National Polyptide Drug Preparation Technology Platform, National High -tech Industry The demonstration project, polypeptide drug production base, and have undertaken a number of national -level topics, and have won national, provincial, and municipal special science and technology awards for many years.

Smart bud data shows that Shenzhen Hanyu Pharmaceutical Co., Ltd. and its affiliated companies have applied for a total of 730 patents, of which more than 620 invention patents, accounting for more than 85%. Except for China, the company has a patented technology layout in Europe, the United States, Germany, India and other countries/regions. By further analyzing its patented technology data, the company's patented technology is mainly deployed in the fields of solid phase synthesis, amino acids, peptide resins, and injection pens.

- END -